Redx Pharma plc Director/PDMR Shareholding (4613W)

TIDMREDX

RNS Number : 4613W

Redx Pharma plc

14 November 2017

REDX PHARMA PLC

("Redx" or "the Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

Alderley Park, November 14 2017- Redx Pharma (AIM:REDX), the drug discovery and development company, announces that is has been notified that Iain Ross, Executive Chairman, has today acquired 348,000 Redx ordinary shares at a price of 18.036 pence per share. Following this, Mr Ross will hold 348,000 ordinary shares in the Company, representing 0.28 per cent. of the issued share capital.

Mr Ross purchased the shares through his self-invested personal pension (SIPP) and the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ------------------------------------------------------------------- 
 a)   Name                      Iain Ross 
---  ------------------------  ----------------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------------- 
 a)   Position/status           Executive Chairman 
---  ------------------------  ----------------------------------------- 
 b)   Initial notification/     Initial notification 
       Amendment 
---  ------------------------  ----------------------------------------- 
 3    Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or 
       auction monitor 
---  ------------------------------------------------------------------- 
 a)   Name                      Redx Pharma plc 
---  ------------------------  ----------------------------------------- 
 b)   LEI                       213800HMS4EBXO589Y37 
---  ------------------------  ----------------------------------------- 
 4    Details of the transaction(s): section to be 
       repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and 
       (iv) each place where transactions have been 
       conducted 
---  ------------------------------------------------------------------- 
 a)   Description of            Ordinary shares of 1 pence 
       the financial             ISIN: GB00BSNB6S51 
       instrument, type 
       of instrument 
       Identification 
       code 
---  ------------------------  ----------------------------------------- 
 b)   Nature of the             Purchase of shares through self-invested 
       transaction               personal pension (SIPP) 
---  ------------------------  ----------------------------------------- 
 c)   Price(s) and              348,000 ordinary shares at a price 
       volume(s)                 of 18.036 pence per share 
---  ------------------------  ----------------------------------------- 
 d)   Aggregated information    N/A 
       - Aggregated 
       volume 
       - Price 
---  ------------------------  ----------------------------------------- 
 e)   Date of the transaction   14 November 2017 
---  ------------------------  ----------------------------------------- 
 f)   Place of the              London Stock Exchange, AIM (XLON) 
       transaction 
---  ------------------------  ----------------------------------------- 
 

For further information, please contact:

 
Redx Pharma Plc                      T: +44 1625 
                                      469 918 
Iain Ross, Executive Chairman 
 
Cantor Fitzgerald Europe (Nominated   T: +44 20 
 Advisor & Broker)                     7894 7000 
Phil Davies 
 
WG Partners LLP (Joint Broker)       T: +44 20 
                                      3705 9330 
Claes Spång/ Chris Lee/ David 
 Wilson 
 
FTI Consulting                       T: +44 20 
                                      3727 1000 
Simon Conway/Stephanie Cuthbert 
 

About Redx Pharma Plc

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of oncology and fibrosis that address significant unmet medical need. Redx has a significant in-house discovery team with proven world-class chemistry capabilities.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUSUARBVAAAAA

(END) Dow Jones Newswires

November 14, 2017 06:30 ET (11:30 GMT)